Peptide Stacking with GLP-1s: What People Are Combining with Ozempic and Mounjaro
Evidence for an individual peptide does not establish that adding it to semaglutide or tirzepatide improves muscle, gastrointestinal symptoms, or skin outcomes.
Key points
- SEMALEAN studied semaglutide and did not test a peptide stack.
- BPC-157 has limited human reports, but the cited research does not establish protection against GLP-1 gastrointestinal effects.
- The tesamorelin trial involved adults with HIV and abdominal fat accumulation, not a general GLP-1-treated population.
- Evidence about a mechanism, an individual compound, or topical use cannot establish the benefits or safety of an injected combination.
Correction — September 6, 2026
We corrected source identifiers and replaced a misidentified Vanderbilt cohort with the actual SEMALEAN study. We also removed unsupported claims about prescribing patterns, combination benefits, and clinical protocols.
Why People Consider Adding Another Peptide
Weight loss, gastrointestinal symptoms, and changes in skin appearance prompt questions about adding other products to GLP-1 treatment. A plausible mechanism is a reason to investigate a combination; it does not establish a benefit or a safe treatment protocol.
The relevant question is whether the specific combination has been evaluated for the outcome and population being discussed. Evidence from separate studies of separate compounds cannot answer that question.
What the Body-Composition Source Actually Studied
The cited SEMALEAN study was a prospective semaglutide study, not the 1,809-patient Vanderbilt comparison previously described here. It enrolled 115 people with obesity; 106 completed follow-up. Lean mass declined during the first seven months and then stabilized, while handgrip strength improved by twelve months.
It did not test adding CJC-1295, ipamorelin, or tesamorelin. Its findings also illustrate why a lean-mass change cannot automatically be described as an equivalent loss of muscle function.
BPC-157: Limited Human Reports Do Not Establish GI Protection
The 2025 orthopaedic systematic review included 35 preclinical studies and one clinical report within a search ending in June 2024. More recent small human reports exist, as discussed in our BPC-157 evidence review.
That is not evidence that BPC-157 prevents nausea, constipation, or other gastrointestinal effects during GLP-1 treatment. Calling the human literature entirely absent was too broad; treating the animal findings as a reason to recommend this combination was also unsupported.
Tesamorelin: Population and Indication Matter
The cited 2014 randomized trial enrolled 50 adults with HIV and abdominal fat accumulation. It assessed visceral and liver fat over six months. It did not test a GLP-1 combination or establish a treatment for fatty liver in the general population.
Visceral-fat reduction is not the same endpoint as preserving strength during GLP-1-associated weight loss. The trial cannot establish that adding a growth-hormone-releasing drug supplies that benefit.
MOTS-c and GHK-Cu: Mechanism Is Not Combination Evidence
The MOTS-c exercise paper and GHK-Cu review cited below provide biological context. They do not establish that adding these products to a GLP-1 medicine improves metabolic function or prevents loose skin. Human observations of an endogenous peptide are different from trials administering it. Topical cosmetic findings cannot establish the effects or safety of injections.
Claims that these are established prescribing patterns, or that one is the most effective or most logical stack, were not supported by the cited sources and have been removed.
Discuss the Actual Problem Before Adding Treatment
Persistent gastrointestinal symptoms, difficulty eating adequately, or changes in strength deserve a discussion with the prescriber. Nutrition and activity plans should account for health conditions and treatment tolerance.
For any proposed additional medicine, ask what study tested that particular combination, what outcome improved, and what harms were measured. The sources reviewed here do not establish a self-directed wellness-peptide stacking protocol.
Limitations
- This review evaluates the sources attached to the combinations discussed; it is not an exhaustive registry search of every GLP-1 combination trial.
- The relevant studies differ in design, population, route, and outcomes.
- The cited sources do not establish a clinical dosing or monitoring protocol for these wellness combinations.
Citations
- 1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewSystematic Review 2025
- 2. Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected PatientsClinical Trial JAMA 2014
- 3. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)Clinical Trial N Engl J Med 2021
- 4.
- 5. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN studyObservational Study Diabetes, Obesity and Metabolism 2026
- 6. MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical DeclineResearch Nat Commun 2021
Peptides in this article
Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.
Related insights
Federal Employees and GLP-1s in 2027: Required Behavioral Therapy, Higher Costs, and How to Pay Less
Every FEHB and PSHB plan will require documented intensive behavioral therapy before and during weight-loss GLP-1 treatment in 2027, and many plans are raising member costs to 50%. A guide for federal employees, postal workers, and retirees before Open Season ends December 14.
Can Wegovy or Ozempic Make You Fail a Breathalyzer? Ketones, Ignition Interlocks, and False Positives
A November 2026 case report describes a woman with years of sobriety who failed two ignition interlock breath tests days after raising her Wegovy dose. Eating much less can push the body to make a compound that some breath alcohol devices read as alcohol. The evidence is thin, but drivers with interlocks should know how it could happen and what to do.
How to Dispose of Used Ozempic, Zepbound, and Wegovy Pens, Peptide Syringes, and Needles: Sharps Rules in the U.S., UK, and Australia
New York City just raised its fine for loose needles in the trash to $250 after needle-stick injuries among sanitation workers nearly doubled. Here is what goes in a sharps container, what can go in the trash, and how to get rid of a full container where you live.